In order to formulate a policy for promoting bulk drug manufacturing in the country, the government has been evaluating recommendations of a committee formed to study issues related to critical active pharmaceutical ingredients (APIs). The government, while taking various measures for promoting 'Make in India' initiative in pharmaceutical sector had constituted a committee under the chairmanship of Secretary, Department of Health Research in this direction.
The committee, among many other things recommended establishment of Mega Parks for APIs with common facilities such as common effluent treatment plants, testing facilities, captive power plants/assured power supply by state systems, common utilities /services such as storage, testing laboratories, IPR management, designing, guest houses/accommodation etc maintained by a separate special purpose vehicles (SPV).
Basically, the policy is being contemplated to reduce dependence on imports. This could be done so by making changes to the existing regulations to promote medical devices production is being chalked out by the Centre. Notably, the measures, in various stages of formulation, are focused on providing impetus to the pharmaceutical industry and making medicines as well as medical devices affordable and accessible.